Gene expression signature: A powerful approach for drug discovery in diabetes

Journal of Endocrinology

Volumn 232, Issue 2, 2017, Pages R131-R139

  Sithara, Smithamol ^a   Crowley, Tamsyn M ^a   Walder, Ken ^a   Aston Mourney, Kathryn ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Complex disease; Drug discovery; Gene expression signature; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; NEW DRUG; TRANSCRIPTOME;

DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG IDENTIFICATION; GENE EXPRESSION; GENE EXPRESSION SIGNATURE; GENETIC ANALYSIS; HUMAN; IMMUNE COMPLEX DISEASE; MALIGNANT NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; DIABETES MELLITUS, TYPE 2; DRUG DEVELOPMENT; GENETICS;

DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; TRANSCRIPTOME;

EID: 85012008485     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0515     Document Type: Review

References (95)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 503-511. (doi:10.1038/35000501)
2. Andersen MK, Pedersen CE, Moltke I, Hansen T, Albrechtsen A & Grarup N 2016 Genetics of Type 2 Diabetes: the Power of Isolated Populations. Current Diabetes Reports 16 65. (doi:10.1007/s11892-016-0757-z)
3. Antipova AA, Stockwell BR & Golub TR 2008 Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biology 9 R47-R47. (doi:10.1186/gb-2008-9-3-r47)
4. Ashcroft FM & Rorsman P 2012 Diabetes mellitus and the β cell: the last ten years. Cell 148 1160-1171. (doi:10.1016/j.cell.2012.02.010)
5. American Diabetes Association 2016 Obesity management for the treatment of type 2 diabetes. Sec. 6. In Standards of Medical Care in Diabetes-2016. Diabetes Care 39 S47-S51. (doi:10.2337/dc16-S009)
6. Aston-Mourney K, Proietto J, Morahan G & Andrikopoulos S 2008 Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia 51 540-545. (doi:10.1007/s00125-008-0930-2)
7. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, et al. 2004 Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology 22 2284-2293. (doi:10.1200/JCO.2004.05.166)
8. Ayoub WA, Kumar AA, Naguib HS & Taylor HC 2010 Exenatide-induced acute pancreatitis. Endocrine Practice 16 80-83. (doi:10.4158/EP09104.CRR)
9. Bensellam M, Laybutt DR & Jonas JC 2012 The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Molecular and Cellular Endocrinology 364 1-27. (doi:10.1016/j.mce.2012.08.003)
10. Berhan A & Barker A 2013 Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 13 58. (doi:10.1186/1472-6823-13-58)
11. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, et al. 2010 An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 973-977. (doi:10.1038/nature09247)
12. Biden TJ, Boslem E, Chu KY & Sue N 2014 Lipotoxic endoplasmic reticulum stress, beta cell failure, and type 2 diabetes mellitus. Trends in Endocrinology and Metabolism 25 389-398. (doi:10.1016/j. tem.2014.02.003)
13. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, et al. 2009 One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32 762-768. (doi:10.2337/dc08-1797)
14. Buse JB, Tan MH, Prince MJ & Erickson PP 2004 The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 6 133-156. (doi:10.1111/j.1462-8902.2004.00325.x)
15. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA & Butler PC 2003 Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 102-110. (doi:10.2337/diabetes.52.1.102)
16. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA & Cersosimo E 2008 Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology: Endocrinology and Metabolism 294 E846-E852. (doi:10.1152/ajpendo.00030.2008)
17. Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P & Nevins JR 2011 SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics 12 443. (doi:10.1186/1471-2105-12-443)
18. Chao EC & Henry RR 2010 SGLT2 inhibition-a novel strategy for diabetes treatment. Nature Reviews Drug Discovery 9 551-559. (doi:10.1038/nrd3180)
19. Chibon F 2013 Cancer gene expression signatures-the rise and fall? European Journal of Cancer 49 2000-2009. (doi:10.1016/j. ejca.2013.02.021)
20. Chu CA, Wiernsperger N, Muscato N, Knauf M, Neal DW & Cherrington AD 2000 The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. Metabolism 49 1619-1626. (doi:10.1053/meta.2000.18561)
21. Dabhi AS, Bhatt NR & Shah MJ 2013 Voglibose: an alpha glucosidase inhibitor. Journal of Clinical and Diagnostic Research 7 3023-3027. (doi:10.7860/JCDR/2013/6373.3838)
22. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, Mexican American Type 2 Diabetes (MAT2D) Consortium, Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, et al. 2014 Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nature Genetics 46 234-244. (doi:10.1038/ng.2897)
23. Drucker DJ & Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 1696-1705. (doi:10.1016/S0140-6736(06)69705-5)
24. Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W & Fahrbach JL 2014 Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 1349-1357. (doi:10.1016/S0140-6736(14)60976-4)
25. Elashoff M, Matveyenko AV, Gier B, Elashoff R & Butler PC 2011 Pancreatitis, pancreatic, and thyroid cancer with glucagonlike peptide-1-based therapies. Gastroenterology 141 150-156. (doi:10.1053/j.gastro.2011.02.018)
26. Erondu N, Desai M, Ways K & Meininger G 2015 Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38 1680-1686. (doi:10.2337/dc15-1251)
27. Esguerra J, Mollet I, Salunkhe V, Wendt A & Eliasson L 2014 Regulation of pancreatic beta cell stimulus-secretion coupling by microRNAs. Genes 5 1018-1031. (doi:10.3390/genes5041018)
28. Evans WE & Guy RK 2004 Gene expression as a drug discovery tool. Nature Genetics 36 214-215. (doi:10.1038/ng0304-214)
29. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC & Woerle HJ 2014 Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. Journal of Clinical Investigation 124 499-508. (doi:10.1172/JCI72227)
30. Fineman MS, Shen LZ, Taylor K, Kim DD & Baron AD 2004 Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes/Metabolism Research and Reviews 20 411-417. (doi:10.1002/dmrr.499)
31. Florez H, Luo J, Castillo-Florez S, Mitsi G, Hanna J, Tamariz L, Palacio A, Nagendran S & Hagan M 2010 Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgraduate Medicine 122 112-120. (doi:10.3810/pgm.2010.03.2128)
32. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, et al. 2005 Gene expression profile associated with response to doxorubicinbased therapy in breast cancer. Clinical Cancer Research 11 7434-7443. (doi:10.1158/1078-0432.CCR-04-0548)
33. Fu AZ, Qiu Y, Davies MJ & Engel SS 2012 Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Therapy 3 12. (doi:10.1007/s13300-012-0012-9)
34. Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombes M, Princen HM, Havekes LM, Rensen PC & Guigas B 2014 Metformin lowers plasma triglycerides by promoting VLDLtriglyceride clearance by brown adipose tissue in mice. Diabetes 63 880-891. (doi:10.2337/db13-0194)
35. Gegick CG & Altheimer MD 2004 Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Current Medical Research and Opinion 20 919-930. (doi:10.1185/03007 9904125003908)
36. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM & Butler PC 2012 Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61 1250-1262. (doi:10.2337/db11-1109)
37. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, Clausen JO, Rasmussen SS, Jorgensen T, Sandbaek A, et al. 2007 Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10, 705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56 3105-3111. (doi:10.2337/db07-0856)
38. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U & Shaw JE 2014 Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice 103 137-149. (doi:10.1016/j.diabres.2013.11.002)
39. Heller C, Kuhn MC, Mulders-Opgenoorth B, Schott M, Willenberg HS, Scherbaum WA & Schinner S 2011 Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic beta-cell proliferation. American Journal of Physiology: Endocrinology and Metabolism 301 E864-E872. (doi:10.1152/ajpendo.00144.2011)
40. Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH & Almdal T 2014 Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2 E162-E175. (doi:10.9778/cmajo.20130073)
41. Hull RL, Westermark GT, Westermark P & Kahn SE 2004 Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89 3629-3643. (doi:10.1210/jc.2004-0405)
42. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V & Shulman GI 1998 Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine 338 867-872. (doi:10.1056/NEJM199803263381303)
43. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf H, Ziegler A & Kaufmann SE 2007 Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. Journal of Molecular Medicine 85 613-621. (doi:10.1007/s00109-007-0157-6)
44. Jansen MPHM, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LCJ, et al. 2005 Molecular classification of tamoxifenresistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology 23 732-740. (doi:10.1200/JCO.2005.05.145)
45. Jetton TL, Lausier J, LaRock K, Trotman WE, Larmie B, Habibovic A, Peshavaria M & Leahy JL 2005 Mechanisms of compensatory betacell growth in insulin-resistant rats: roles of Akt kinase. Diabetes 54 2294-2304. (doi:10.2337/diabetes.54.8.2294)
46. Kahn SE, Cooper ME & Del Prato S 2014 Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383 1068-1083. (doi:10.1016/S0140-6736(13)62154-6)
47. Kalia M 2013 Personalized oncology: recent advances and future challenges. Metabolism 62 (Supplement 1) S11-S14. (doi:10.1016/j. metabol.2012.08.016)
48. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR & Kahn BB 2002 Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51 443-448. (doi:10.2337/diabetes.51.2.443)
49. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA & Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 346 393-403. (doi:10.1056/NEJMoa012512)
50. Konstantopoulos N, Foletta VC, Segal DH, Shields KA, Sanigorski A, Windmill K, Swinton C, Connor T, Wanyonyi S, Dyer TD, et al. 2011 A gene expression signature for insulin resistance. Physiological Genomics 43 110-120. (doi:10.1152/physiolgenomics.00115.2010)
51. Konstantopoulos N, Molero JC, McGee SL, Spolding B, Connor T, de Vries M, Wanyonyi S, Fahey R, Morrison S, Swinton C, et al. 2012 Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes 61 2146-2154. (doi:10.2337/db11-0578)
52. Kwon DY, Kim YS, Ahn IS, Kim da S, Kang S, Hong SM & Park S 2009 Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. Journal of Pharmacological Sciences 111 361-371. (doi:10.1254/jphs.09178FP)
53. Lai Y-J, Hu H-Y, Chen H-H & Chou P 2015 Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study. Medicine 94 e1906. (doi:10.1097/MD.0000000000001906)
54. Leahy JL 2005 Pathogenesis of type 2 diabetes mellitus. Archives of Medical Research 36 197-209. (doi:10.1016/j.arcmed.2005.01.003)
55. Lehtovirta M, Kaprio J, Forsblom C, Eriksson J, Tuomilehto J & Groop L 2000 Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. Diabetologia 43 285-293. (doi:10.1007/s001250050046)
56. Li F, Cao Y, Han L, Cui X, Xie D, Wang S & Bo X 2013 GeneExpressionSignature: an R package for discovering functional connections using gene expression signatures. Omics 17 116-118. (doi:10.1089/omi.2012.0087)
57. Luzi L, Barrett EJ, Groop LC, Ferrannini E & DeFronzo RA 1988 Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 37 1470-1477. (doi:10.2337/diab.37.11.1470)
58. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, et al. 1998 Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitusa randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 128 176-185. (doi:10.7326/0003-4819-128-3-199802010-00002)
59. McGee SL & Hargreaves M 2010 Histone modifications and skeletal muscle metabolic gene expression. Clinical and Experimental Pharmacology and Physiology 37 392-396. (doi:10.1111/j.1440-1681.2009.05311.x)
60. Misbin RI 2004 The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27 1791-1793. (doi:10.2337/diacare.27.7.1791)
61. Mitka M 2013 More patients get good diabetes control, but only a minority meet all goals. JAMA 309 1335-1336. (doi:10.1001/jama.2013.2414)
62. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ & DeFronzo RA 2001 Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 710-719. (doi:10.2337/diacare.24.4.710)
63. Miyazaki Y, He H, Mandarino LJ & DeFronzo RA 2003 Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52 1943-1950. (doi:10.2337/diabetes.52.8.1943)
64. Motala AA, Omar MA & Gouws E 1993 High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. Diabetes 42 556-563. (doi:10.2337/diab.42.4.556)
65. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L & Alba LM 2010 Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53 153-159. (doi:10.1007/s00125-009-1515-4)
66. NCD-RisC 2016 Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387 1513-1530. (doi:10.1016/S0140-6736(16)00618-8)
67. Nolan CJ, Leahy JL, Delghingaro-Augusto V, Moibi J, Soni K, Peyot ML, Fortier M, Guay C, Lamontagne J, Barbeau A, et al. 2006 Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia 49 2120-2130. (doi:10.1007/s00125-006-0305-5)
68. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC & Hirsch IB 2015 Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 1687-1693. (doi:10.2337/dc15-0843)
69. Proks P, Reimann F, Green N, Gribble F & Ashcroft F 2002 Sulfonylurea stimulation of insulin secretion. Diabetes 51 (Supplement 3) S368-S376. (doi:10.2337/diabetes.51.2007.S368)
70. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, et al. 2009 Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunology 10 116-125. (doi:10.1038/ni.1688)
71. Rabbani B, Tekin M & Mahdieh N 2014 The promise of whole-exome sequencing in medical genetics. Journal of Human Genetics 59 5-15. (doi:10.1038/jhg.2013.114)
72. Royal Australian College of General Practitioners 2016 General Practice Management of Type 2 Diabetes: 2016-18. East Melbourne, Vic, Australia: RACGP. (available at: https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf)
73. Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A, Lango H, Frayling TM, Neumann RJ, Sherva R, et al. 2007 Common variants in WFS1 confer risk of type 2 diabetes. Nature Genetics 39 951-953. (doi:10.1038/ng2067)
74. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, et al. 2012 Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. American Journal of Human Genetics 90 410-425. (doi:10.1016/j. ajhg.2011.12.022)
75. Schadt EE, Friend SH & Shaywitz DA 2009 A network view of disease and compound screening. Nature Reviews Drug Discovery 8 286-295. (doi:10.1038/nrd2826)
76. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al. 2007 A genomewide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 1341-1345. (doi:10.1126/science.1142382)
77. Shah P, Ardestani A, Dharmadhikari G, Laue S, Schumann DM, Kerr-Conte J, Pattou F, Klein T & Maedler K 2013 The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. Journal of Clinical Endocrinology and Metabolism 98 E1163-E1172. (doi:10.1210/jc.2013-1029)
78. Simpson RW, Nicholson GC, Proietto J, Sarah A, Sanders KM, Phillips G, Chambers J, MacGinley R, Orford N, Walder K, et al. 2014 Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study. Diabetes Care 37 3121-3123. (doi:10.2337/dc14-1038)
79. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, et al. 2007 A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445 881-885. (doi:10.1038/nature05616)
80. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
81. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR & Golub TR 2004 Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nature Genetics 36 257-263. (doi:10.1038/ng1305)
82. Steil GM, Trivedi N, Jonas JC, Hasenkamp WM, Sharma A, Bonner-Weir S & Weir GC 2001 Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. American Journal of Physiology: Endocrinology and Metabolism 280 E788-E796.
83. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, et al. 2010 Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clinical Cancer Research 16 5351-5361. (doi:10.1158/1078-0432.CCR-10-1265)
84. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 344 1343-1350. (doi:10.1056/NEJM200105033441801)
85. Unger J & Parkin C 2011 Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgraduate Medicine 123 81-91. (doi:10.3810/pgm.2011.07.2307)
86. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536. (doi:10.1038/415530a)
87. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, et al. 2010 Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genetics 42 579-589. (doi:10.1038/ng.609)
88. Wang C, Chen X, Ding X, He Y, Gu C & Zhou L 2015 Exendin-4 promotes beta cell proliferation via PI3k/Akt signalling pathway. Cellular Physiology and Biochemistry 35 2223-2232. (doi:10.1159/000374027)
89. Wang L, Shen X, Wang Z, Xiao X, Wei P, Wang Q, Ren F, Wang Y, Liu Z, Sheng W, et al. 2015 A molecular signature for the prediction of recurrence in colorectal cancer. Molecular Cancer 14 22. (doi:10.1186/s12943-015-0296-2)
90. Weeks DE & Lathrop GM 1995 Polygenic disease: methods for mapping complex disease traits. Trends in Genetics 11 513-519. (doi:10.1016/S0168-9525(00)89163-5)
91. Weir GC & Bonner-Weir S 2004 Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 (Supplement 3) S16-S21. (doi:10.2337/diabetes.53.suppl_3.S16)
92. Yin ZQ, Liu JJ, Xu YC, Yu J, Ding GH, Yang F, Tang L, Liu BH, Ma Y, Xia YW, et al. 2014 A 41-gene signature derived from breast cancer stem cells as a predictor of survival. Journal of Experimental and Clinical Cancer Research 33 49. (doi:10.1186/1756-9966-33-49)
93. Zaas AK, Chen M, Varkey J, Veldman T, Hero Iii AO, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, et al. 2009 Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host and Microbe 6 207-217. (doi:10.1016/j.chom.2009.07.006)
94. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, et al. 2008 Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 40 638-645. (doi:10.1038/ng.120)
95. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. 2001 Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108 1167-1174. (doi:10.1172/JCI13505)